Patents by Inventor Hongfu LU

Hongfu LU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF
    Publication number: 20240116935
    Abstract: Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
    Type: Application
    Filed: November 13, 2023
    Publication date: April 11, 2024
    Inventors: Hongfu LU, Huaxing YU, Xiao DING, Feng REN
  • NOVEL BENZAZEPINE SPIRO DERIVATIVE
    Publication number: 20240101568
    Abstract: A benzazepine spiro derivative as represented by formula (I) and a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and/or treatment of diseases related to vasopressin receptors.
    Type: Application
    Filed: November 25, 2021
    Publication date: March 28, 2024
    Inventors: Hongfu LU, Yongcong LV, Yan YE, Jianbiao PENG, Haibing GUO
  • DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF
    Publication number: 20240051958
    Abstract: Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 15, 2024
    Inventors: Hongfu LU, Huaxing YU, Xiao DING, Feng REN
  • Phthalazinone compound, and preparation method therefor and medical use thereof
    Patent number: 11767312
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Grant
    Filed: April 5, 2023
    Date of Patent: September 26, 2023
    Assignee: GENENTECH, INC.
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20230242510
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Application
    Filed: April 5, 2023
    Publication date: August 3, 2023
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20230131252
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 27, 2023
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION
    Publication number: 20230111119
    Abstract: Provided are a protein degradation agent compound preparation method and application; specifically, provided are the compound represented by formula (I) and a pharmacologically acceptable salt thereof, and an application of said compound in the degradation of androgen receptor (AR).
    Type: Application
    Filed: December 23, 2020
    Publication date: April 13, 2023
    Inventors: Hongfu LU, Weiqiang XING, Baojian QI, Jianbiao PENG, Haibing GUO
  • AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE
    Publication number: 20220017513
    Abstract: Relating to a compound represented by formula (I) and a pharmaceutically acceptable salt of the compound, and an application of the compound as an S1P1 agonist.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Applicants: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD, JIANGXI JEMINCARE GROUP CO., LTD
    Inventors: Hongfu LU, Jianbiao PENG, Weiqiang XING, Haibing GUO
  • 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors
    Patent number: 10336719
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 2, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • Novel Compounds
    Publication number: 20190010135
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 10, 2019
    Inventors: Weichun Chen, Ebere F. Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors
    Patent number: 10106515
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: October 23, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lingdong Zhu
  • 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS
    Publication number: 20170190681
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation
    Type: Application
    Filed: May 27, 2015
    Publication date: July 6, 2017
    Applicant: Glaxosmithline Intellectual Property Development Limited
    Inventors: Weichun CHEN, Ebere F. IGBOKO, Xichen LIN, Hongfu LU, Feng REN, Paul Bryan WREN, Zhongmiao XU, Ting YANG, Lingdong ZHU